FDA approves Merck’s Keytruda in combination with carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer

The approval of the KEYTRUDA combination for patients with primary advanced or recurrent endometrial cancer is based on results from the NRG-GY018/KEYNOTE-868 clinical trial, a Phase III study evaluating the combination of anti-PD-1 immunotherapy and chemotherapy in patients with two different tumor types.